- Acquired by AstraZeneca
- Michael H. Davidson, Jerry Wisler
- Princeton, NJ
- Went Public on Apr 11, 2013
- Health and Wellness, Medical, Pharmaceuticals, Biotechnology
- Omthera Pharmaceuticals develops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease.
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.
Current Team (3)Update
Funding Rounds (4) - $60.2MUpdate
Board Members and Advisors (3)Update
707 State Road
Princeton, NJ 08540
- 04/11/13 -nasdaq.com